|
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® to treat a range of serious human diseases. Nanobodies® are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and extreme stability, Nanobodies® combine the advantages of conventional antibody therapeutics with the key features of small-molecule drugs. More… |
Listed on Euronext Brussels in 2007 |
|
AMT is a pioneer in the development of gene therapy for the treatment of severe (orphan) diseases. More… |
Listed on Euronext Amsterdam in 2007 |
|
CropDesign is an agricultural biotech company which has developed a platform and a portfolio of traits to enhance yeild and drought resistance in major field crops. More… |
Acquired by BASF Plant Science in 2006 |
|
FlowCardia, Inc. is a medical device company established in 2002 to design and manufacture safe and effective, endovascular CTO recanalization systems. More… |
Acquired by C. R. Bard, Inc. (NYSE: BCR) |
|
GlycArt has developed glycoengineering technology (GlycoMAb®) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. In addition GLYCART has developed additional proprietary technologies covering all key elements of the monoclonal antibody value chain. More… |
Acquired by Roche in 2005 |
|
Innate Pharma develops drugs targeting the innate immune system. This innovative approach - currently in clinical development - opens the way to new therapeutic solutions in canceras well as in infectious diseases and chronic inflammatory pathologies. More… |
Listed on Euronext Paris in 2006 |
|
Inpharmatica specialises in the use of predictive informatics in medicinal chemistry and ADME to improve the speed and productivity of drug discovery. More… |
Acquired by Galapagos in 2006 |
|
Neuro3d develops drugs against psychiatric disorders such as schizophrenia and depression. More… |
Acquired by Evotec in 2007 |
